Teckro raises $10M series B to expand clinical trial digitization services

Machine learning-focused software company Teckro has raised $10 million in series B financing to advance its clinical trial digital platform.

Machine learning-focused software company Teckro has raised $10 million in series B financing, sending the total amount it has attracted so far to $17.8 million.

The money will be used to improve the company’s digital platform, which uses information retrieval and machine learning technologies to streamline clinical trial practices. The idea is that, instead of filtering through protocols, medical journals and emails, clinical study personnel could save time by using Teckro’s software to simplify the trial process.

The platform, which can support all phases of trials, is already being used at thousands of research sites in over 30 countries, and the company continues to expand operations and customer footprint globally and to “drive success for our customers at the top 10 pharmaceutical and biotech companies,” Teckro CEO Gary Hughes said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Teckro co-founders Hughes, Jacek Skrzypiec and Gary Hughes previously built Firecrest Clinical into a 60-person team before selling it and its site-performance management software to Icon in 2011.

Sands Capital Ventures, a Washington, D.C.-area venture capital firm, led the financing round. Peter Thiel’s Founders Fund, backers of tech firms like SpaceX, Facebook and Airbnb, led a previous $6 million investment into Teckro, and is also part of this financing round. Other participants include startup tech-focused venture fund Section 32, which was launched by Google Ventures’ founder and former CEO Bill Maris.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.